AbbVie board OKs $1.5B for share buybacks

AbbVie, drugmaker newly spun off by Abbott, puts aside $1.5B for buybacks

RELATED QUOTES

SymbolPriceChange
ABT37.760.28
ABBV.PA36.503.70
ABBV.SW45.50-0.55
ABBV45.44-1.15
4AB.F36.100.08

NORTH CHICAGO, Ill. (AP) -- Drugmaker AbbVie Inc., spun off from Abbott Laboratories in January, approved $1.5 billion for buying back its own shares.

The company expects the stock purchases to be completed over several years. Buybacks can make shareholders' existing holdings more valuable and boost earnings per share.

AbbVie, based in North Chicago, Ill., sells branded prescription drugs, including the blockbuster anti-inflammatory drug Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn's Disease.

Abbott, meanwhile, will continue marketing the company's remaining products: Nutritional formula, generic drugs and medical devices.

Company shares rose 98 cents, or 2.7 percent, to $37.55 in premarket trading.

  •  
    Recent Quotes
    Symbol Price Change % ChgChart 
    Your most recently viewed tickers will automatically show up here if you type a ticker in the "Enter symbol/company" at the bottom of this module.
    You need to enable your browser cookies to view your most recent quotes.
  • Recent Quotes News

    •  
      Sign-in to view quotes in your portfolios.

    Trading Center

    Yahoo! Finance on Facebook

    POLL

    In the wake of the Washington state bridge collapse, would you support a tax hike for infrastructure projects?

    Loading...
    Poll Choice Options